Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Journal of Autoimmune Diseases

Figure 3

From: Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study

Figure 3

Upper panel : (3A) MPO-ANCA inhibition assay. Incubation with increasing concentrations of myeloperoxidase (MPO) (1 – 20 μg/mL) leads to a reduction in MPO-ANCA reactivity (■). In contrast, incubation with human Heat Shock Protein 60 (hHSP60) (1 – 20 μg/mL) does not decrease MPO-ANCA reactivity (). Lower panel: (3B) Anti-human Heat Shock Protein 60 (hHSP60) inhibition assay. Incubation with increasing concentrations of myeloperoxidase (MPO) (1 – 20 μg/mL) does not lead to a reduction in anti-hHSP60 reactivity (■). However, incubation with hHSP60 (1 – 20 μg/mL) only slightly decreases anti-hHSP60 reactivity ()

Back to article page